Inmune Bio (INMB) EBIAT (2018 - 2025)
Historic EBIAT for Inmune Bio (INMB) over the last 7 years, with Q3 2025 value amounting to -$6.5 million.
- Inmune Bio's EBIAT rose 4648.14% to -$6.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$49.9 million, marking a year-over-year decrease of 2091.73%. This contributed to the annual value of -$42.1 million for FY2024, which is 4029.59% down from last year.
- Inmune Bio's EBIAT amounted to -$6.5 million in Q3 2025, which was up 4648.14% from -$24.5 million recorded in Q2 2025.
- Inmune Bio's 5-year EBIAT high stood at -$4.6 million for Q1 2021, and its period low was -$24.5 million during Q2 2025.
- Moreover, its 5-year median value for EBIAT was -$8.4 million (2023), whereas its average is -$9.0 million.
- The largest annual percentage gain for Inmune Bio's EBIAT in the last 5 years was 4648.14% (2025), contrasted with its biggest fall of 15095.42% (2025).
- Over the past 5 years, Inmune Bio's EBIAT (Quarter) stood at -$9.7 million in 2021, then surged by 39.69% to -$5.8 million in 2022, then tumbled by 44.15% to -$8.4 million in 2023, then fell by 9.85% to -$9.2 million in 2024, then increased by 29.93% to -$6.5 million in 2025.
- Its EBIAT was -$6.5 million in Q3 2025, compared to -$24.5 million in Q2 2025 and -$9.7 million in Q1 2025.